Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial

AA Moccia, C Taverna, S Schär, A Vanazzi… - Blood …, 2020 - ashpublications.org
Abstract The Swiss Group for Clinical Cancer Research (SAKK) conducted the SAKK 35/03
randomized trial (NCT00227695) to investigate different rituximab monotherapy schedules …
被引用次数：14 相关文章

Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial

AA Moccia, C Taverna, S Schär, A Vanazzi, S Rondeau… - Blood Advances, 2020 - Elsevier
Abstract The Swiss Group for Clinical Cancer Research (SAKK) conducted the SAKK 35/03
randomized trial (NCT00227695) to investigate different rituximab monotherapy schedules …

Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial

AA Moccia, C Taverna, S Schär, A Vanazzi, S Rondeau… - 2020 - pubmed.ncbi.nlm.nih.gov
The Swiss Group for Clinical Cancer Research (SAKK) conducted the SAKK 35/03
randomized trial (NCT00227695) to investigate different rituximab monotherapy schedules …
[PDF] researchgate.net

[PDF][PDF] Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial

AA Moccia, C Taverna, S Schär, A Vanazzi, S Rondeau… - 2020 - researchgate.net
Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma (NHL),
accounting for; 35% of NHL cases. 1 Although the past 2 decades have seen important …
[PDF] archive.org

[PDF][PDF] Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial

AA Moccia, C Taverna, S Schär, A Vanazzi, S Rondeau… - 2020 - scholar.archive.org
Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma (NHL),
accounting for; 35% of NHL cases. 1 Although the past 2 decades have seen important …
[HTML] nih.gov

[HTML][HTML] Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial

AA Moccia, C Taverna, S Schär, A Vanazzi… - Blood …, 2020 - ncbi.nlm.nih.gov
Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK
35/03 randomized trial - PMC Back to Top Skip to main content NIH NLM Logo Access keys …

Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial.

AA Moccia, C Taverna, S Schär, A Vanazzi… - Blood …, 2020 - boris.unibe.ch
The Swiss Group for Clinical Cancer Research (SAKK) conducted the SAKK 35/03
randomized trial (NCT00227695) to investigate different rituximab monotherapy schedules …
[PDF] academia.edu

[PDF][PDF] Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial

AA Moccia, C Taverna, S Schär, A Vanazzi, S Rondeau… - 2020 - academia.edu
Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma (NHL),
accounting for; 35% of NHL cases. 1 Although the past 2 decades have seen important …

Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial.

AA Moccia, C Taverna, S Schär, A Vanazzi… - Blood …, 2020 - europepmc.org
Abstract The Swiss Group for Clinical Cancer Research (SAKK) conducted the SAKK 35/03
randomized trial (NCT00227695) to investigate different rituximab monotherapy schedules …
[PDF] researchgate.net

[PDF][PDF] Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial

AA Moccia, C Taverna, S Schär, A Vanazzi, S Rondeau… - 2020 - researchgate.net
Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma (NHL),
accounting for; 35% of NHL cases. 1 Although the past 2 decades have seen important …